Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 796-807

  Chang, A E ^a   Aruga, A ^a   Cameron, M J ^a   Sondak, V K ^a   Normolle, D P ^a   Fox, B A ^a   Shu, S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD3 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY SPECIFICITY; ARTICLE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; LYMPH NODE CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0031027417     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.796     Document Type: Article

References (28)

1. Shu S, Chou C, Sakai K: Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143:740-748, 1989
2. Geiger JD, Wagner PD, Cameron MJ, et al.: Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunol 13:153-165, 1993
3. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-737, 1991
4. Aruga A, Shu S, Chang AE: Tumor-specific granulocyte/macrophage colony-stimulating factor and Interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 41:317-324, 1995
5. Chou T, Bertera S, Chang AE, et al.: Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141:1775-1781, 1988
6. Greenberg PD: Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355, 1991
7. Chang AE, Shu S: Current status of adoptive immunotherapy cancer. Crit Rev Oncol Hematol 22:213-228, 1996
8. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79:1067-1075, 1987
9. Grossland KD, Lee VK, Chen W, et al.: T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 146:4414-4420, 1991
10. Massaro AF, Schoof DD, Rubinstein A, et al.: Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res 50:2587-2592, 1990
11. + tumor-infiltrating lymphocytes. J Exp Med 173:647-658, 1991
12. Goedegebuure PS, Zuber M, Leonard-Vidal DL, et al.: Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: In vitro cytokine production is associated with in vivo efficacy. Surg Oncol 3:79-89, 1994
13. Chang AE, Yoshizawa H, Sakai K, et al.: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993
14. Van Der Bruggen P, Traversari C, Chomez P, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1648, 1991
15. Cox AL, Skipper J, Chen Y, et al.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-720, 1994
16. Kawakami Y, Zakut R, Topalian SL, et al.: Shared human melanoma antigens: Recognition by tumor-infiltrating lymphocytes in HL-A-A2.1 transfected melanomas. J Immunol 148:638-643, 1992
17. Anichini A, Mortarini R, Maccalli C, et al.: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156:208-217, 1996
18. Bianchi ATJ, Hooijkaas H, Benner R, et al.: Clones of helper T cells mediate antigen-specific, H-2 restricted DTH. Nature 290:62-63, 1981
19. Berd D, Maguire HC, McCue P, et al.: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867, 1990
20. Berd D, Maguire HC, Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572-2577, 1986
21. Galligioni E, Quaia M, Merlo A, et al.: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin. Cancer 77:2560-2566, 1996
22. Krauss JC, Strome SE, Chang AE, et al.: Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother 16:77-84, 1994
23. Area MJ, Krauss JC, Aruga A, et al.: Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 3:39-47, 1996
24. Area MJ, Krauss JC, Strome SE, et al.: Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 42:237-245, 1996
25. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 179:1109-1118, 1994
26. Rosenberg S, Yang J, Topalian S, et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-914, 945-946, 1994
27. Yang J, Topalian S, Parkinson D, et al.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
28. Chang AE, Sondak VK, Bishop DK, et al.: Adoptive immunotherapy of cancer primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 7:773-792, 1996